1269757-29-0 Usage
General Description
The chemical (3R,5R)-(3S,5S)-1-(benzyloxycarbonyl)-5-methylpiperidine-3-carboxylic acid is a compound with four chiral centers, and exists as a pair of enantiomers. It is used as a building block in the synthesis of various pharmaceuticals and organic compounds. The benzyloxycarbonyl (Cbz) group is often used as a protecting group for amines, and the presence of a carboxylic acid group makes it useful for peptide synthesis. The methyl and piperidine groups contribute to its structural and chemical properties. (3R,5R)-/(3S,5S)-1-(benzyloxycarbonyl)-5-methylpiperidine-3-carboxylic acid is important in the field of organic chemistry and pharmaceutical research due to its versatility and potential applications in drug development and synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 1269757-29-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,9,7,5 and 7 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1269757-29:
(9*1)+(8*2)+(7*6)+(6*9)+(5*7)+(4*5)+(3*7)+(2*2)+(1*9)=210
210 % 10 = 0
So 1269757-29-0 is a valid CAS Registry Number.
1269757-29-0Relevant articles and documents
N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES
-
, (2012/08/08)
The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.
HETEROARYL COMPOUNDS AS KINASE INHIBITORS
-
, (2011/04/14)
The present invention provides a compound of Formula (I): and pharmaceutically acceptable salts thereof. Also provided is a method of using a compound of Formula I for treating a disease or condition mediated by a CDK inhibitor
